Mannitol — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

6 Recruiting

4 Completed trials

12 Sponsors

20 Countries

Phase III

Phase II

Phase IV

Phase III: 7 Phase II: 2 Phase IV: 2 Phase I (FiH): 1

Oversight events:

1 temporary halt 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Bronchiectasis 1 Neonatal asphyxia 1 Tick-borne viral encephalitis 1 Glycogen storage disease type I 1 Encephalopathy neonatal 1 Small cell lung cancer limited stage 1 Colonoscopy 1 Small cell lung cancer extensive stage 1

Sponsors using this IMP

Amgen Inc. 2 Assistance Publique Hopitaux De Paris 1 Centre Hospitalier Universitaire De Nantes 1 CHU De Liege 1 Hospital Universitari De Girona Doctor Josep Trueta 1 HUS-Yhtymae 1 Moderna Inc. 1 Ntc S.r.l. 1 Region Stockholm – SLSO 1 Region Uppsala 1 Universitaetsklinikum Tuebingen AöR 1 Universite De Liege 1

All trials

12 total

Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending

2025-523476-23-00 Phase II 1 country Region Stockholm – SLSO
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Phase III 12 countries Amgen Inc.
Efficacy of early continuous infusion of hypertonic saline solution on the neurological outcome at 6 months in traumatic brain injured patie… Recruiting

2024-520205-39-00 Phase III 1 country Centre Hospitalier Universitaire De Nantes
Mannitol versus normal saline in brain death donors and recipients of kidney allograft on delayed graft function (MAVERICK) Recruiting

2024-518817-24-01 Phase IV 1 country HUS-Yhtymae
ALBU-CHIP - Efficacy of human 20% albumin solution + Ringer Lactate versus Ringer Lactate for fluid replacement strategy during cytoreductiv… Recruiting

2024-510943-76-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Improved Recovery by Iron following Surgery with blood loss, a double-blind multi-centre randomized controlled phase III drug trial (the IRI… Recruiting

2022-502776-22-00 Phase III 1 country Region Uppsala
Benefits of inhalation of 7% hypertonic saline solution prior to ELTGOL physiotherapy, in patients with bronchiectasis. A randomized control… Recruiting

2024-511677-29-01 Phase IV 1 country Hospital Universitari De Girona Doctor Josep Trueta
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Phase III 16 countries Amgen Inc.
Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study Halted

2023-507404-31-03 Phase II 1 country CHU De Liege; Universite De Liege
A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and p… Ended

2025-521451-23-00 Phase III 5 countries Ntc S.r.l.
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine… Ended

2022-502963-39-00 Phase I (FiH) 4 countries Moderna Therapeutics Inc.
Effect of ALlopurinol in addition to hypothermia for hypoxicischemic Brain Injury on Neurocognitive Outcome Ended

2024-511322-31-00 Phase III 9 countries Universitaetsklinikum Tuebingen AöR

Showing 1–12 of 12 trials

← All drugs A–Z